Editas Medicine
Could I land a role at this company?
Get your resume score and fixes with refresh.cv.
Editas Medicine
Editas Medicine is a leading gene editing company focused on developing CRISPR medicines for people with serious diseases.
Gene Editing
CRISPR Technology
Genomic Medicine
Clinical Research
Rare Diseases
Open roles at Editas Medicine
0 open roles
No open positions at this time
Closed positions
1 positions
Join Our Team
Remote
Closed 3 months ago
Products and services
reni-cel
Gene Therapy
ED
EDIT-101
Gene Therapy
ED
EDIT-301
Cell Therapy
CR
CRISPR Gene Editing Platform
Technology Platform
ED
EDIT-201
Gene Therapy
In Vivo Gene Editing Medicines
Gene Therapy
ED
EDIT-103
Gene Therapy
IN
In Vivo Gene Editing Services
R&D Services
CR
CRISPR/Cas Gene Editing Platform
Platform Technology
EX
Ex Vivo Cell Engineering
R&D Services
EX
Ex Vivo Gene Editing Services
Research Services
EN
Engineered Natural Killer (eNK) Cell Platform
Cell Therapy
ED
EDIT-401
Gene Therapy
Leadership
CS
Charlene Stern
Executive Vice President & General Counsel
KB
Kevin Bitterman
Interim President
DRL
David R. Liu
Founder
FZ
Feng Zhang
Founder
Similar companies
Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.
Foster City, San Mateo County
10,001+ employees
Public
Valuation $85B
172 open jobs
VI
Vir Biotechnology
Immunology-focused biotech
San Francisco, California
201-500 employees
Public
Valuation $1.2B
21 open jobs
Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases.
Thousand Oaks, Ventura County
10,001+ employees
Public
Valuation $138B
1,287 open jobs
Bristol-Myers Squibb
Biopharmaceutical medicines for serious diseases
New York City, New York
10,001+ employees
Public
Valuation $150B
255 open jobs
Quest Diagnostics
American clinical laboratory company
Secaucus, Hudson County
10,001+ employees
Public
Valuation $10.8B
Latest updates
All
X
News
HN
YouTube
Editas Medicine stock has November 9, 2026 earnings date - ad-hoc-news.de
ad-hoc-news.de
News
·
1 week ago
Editas Medicine to present gene editing research at ESGCT congress - Investing.com
Investing.com
News
·
1 week ago
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - GlobeNewswire
GlobeNewswire
News
·
1 week ago
Editas Medicine Q3 2026 Earnings Date and Estimates - MarketBeat
MarketBeat
News
·
1 week ago
Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401 - Yahoo Finance
Yahoo Finance
News
·
2 weeks ago
Show 15 more
Total Views
5
Total Apply Clicks
0
Total Mock Apply
0
Total Bookmarks
0
Reviews
4.2
5 reviews
Work-life balance
4.0
Compensation
3.5
Culture
4.3
Career
2.8
Management
3.5
78%
Recommend to a friend
Pros
Supportive and collaborative team environment
Great work-life balance and flexible hours
Cutting-edge research opportunities
Cons
Limited career advancement opportunities
High expectations and stress levels
Disorganized management practices
Salary Ranges
38 data points
Director
1 reports
-
total per year
Base
$150,000
Stock
-
Contact and location